Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

80 BUPRENORPHINE
Hepatotoxicity
(2006): Prescrire Int 15(82), 64
(2004): Herve S+, Eur J Gastroenterol 16(10), 1033 (5 cases)
(2001): Wisniewski B+, Gastroenterol Clin Biol 25(3), 328
(2000): Petry NM+, Am J Addict 9(3), 265
Injection-site erythema
(2006): Likar R+, Clin Ther 28(6), 943 (12.1%)
Injection-site exanthems
(2006): Likar R+, Clin Ther 28(6), 943 (8.8%)
Injection-site pain
(1993): Torres LM+, Rev Esp Anestesiol Reanim 40(4), 181
Injection-site pruritus
(2006): Likar R+, Clin Ther 28(6), 943
Myalgia/Myositis/Myopathy/Myotoxicity
(2004): Ray R+, Pharmacoepidemiol Drug Saf 13(9), 615 (39.5%)
Neurotoxicity
(2006): Seet RC+, Ann Emerg Med 47(4), 396
Rhabdomyolysis
(2006): Seet RC+, Ann Emerg Med 47(4), 396
*Note: Suboxone contains naloxone
BUPROPION
Trade names: Wellbutrin (GSK); Zyban (GSK)
Indications: Depression, aid to smoking cessation
Category: Antidepressant; Dopamine reuptake inhibitor
Half-life: 14 hours
Clinically important, potentially hazardous interactions
with: cyclosporine, erythromycin, escitalopram, isocarboxazid,
methylphenidate, phenelzine, ritonavir, tranylcypromine,
trimipramine
Reactions
Skin
Acne (1–10%)
Angioedema
Diaphoresis (5%)
(2001): Pederson KJ+, Can J Cardiol 17(5), 599
(1984): Feighner JP+, Am J Psychiatry 141(4), 525
(1983): Feighner JP, J Clin Psychiatry 44, 49
(1981): Halaris AE+, Psychopharmacol Bull 17, 140
Edema (>1%)
(1999): Peloso PM+, JAMA 282, 1817
Erythema multiforme
(2002): Drago F+, Arch Intern Med 162(7), 843
(2001): Carrillo-Jimenez R+, Arch Intern Med 161(12), 1556
(2001): Lineberry TW+, Mayo Clin Proc 76, 664
Exanthems (